Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity
Author(s)
Dougan, S. K.; Dougan, M.; Turner, J. A.; Ogata, S.; Cho, H.-I.; Jaenisch, R.; Celis, E.; Ploegh, H. L.; Kim, Jun; ... Show more Show less
Downloadnihms525714.pdf (2.250Mb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
We have generated, via somatic cell nuclear transfer, two independent lines of transnuclear (TN) mice, using as nuclear donors CD8 T cells, sorted by tetramer staining, that recognize the endogenous melanoma antigen TRP1. These two lines of nominally identical specificity differ greatly in their affinity for antigen (TRP1(high) or TRP1(low)) as inferred from tetramer dissociation and peptide responsiveness. Ex vivo-activated CD8 T cells from either TRP1(high) or TRP1(low) mice show cytolytic activity in 3D tissue culture and in vivo, and slow the progression of subcutaneous B16 melanoma. Although naïve TRP1(low) CD8 T cells do not affect tumor growth, upon activation these cells function indistinguishably from TRP1(high) cells in vivo, limiting tumor cell growth and increasing mouse survival. The anti-tumor effect of both TRP1(high) and TRP1(low) CD8 T cells is enhanced in RAG-deficient hosts. However, tumor outgrowth eventually occurs, likely due to T cell exhaustion. The TRP1 TN mice are an excellent model for examining the functional attributes of T cells conferred by TCR affinity, and they may serve as a platform for screening immunomodulatory cancer therapies.
Date issued
2013-07Department
Massachusetts Institute of Technology. Department of BiologyJournal
Cancer Immunology Research
Publisher
American Association for Cancer Research (AACR)
Citation
Dougan, S. K. et al. “Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity.” Cancer Immunology Research 1, 2 (July 2013): 99–111 © 2013 American Association for Cancer Research (AACR)
Version: Author's final manuscript
ISSN
2326-6066
2326-6074